Research recommendation(s) from an individual piece of guidance
|Date issued:||November 2006|
Research recommendations coming out of this guidance
- For people with vascular dementia, acetylcholinesterase inhibitors and memantine should not be prescribed for the treatment of cognitive decline, except as part of properly constructed clinical studies.
- Memantine is not recommended as a treatment option for people with moderately severe to severe Alzheimer√Ę‚?¨‚?Ęs disease except as part of well-designed clinical studies
- The effect of staff training on behaviour that challenges:- Does training of care staff in dementia-specific person-centred care lead to improvement in behaviour that challenges and reduced prescription of medication to control such behaviour in peop
- Cognitive stimulation and/or acetylcholinesterase inhibitors in Alzheimer√Ę‚?¨‚?Ęs disease.
- Psychological interventions for carers of people with dementia;- For carers of people with dementia, is a psychological intervention cost effective when compared with usual care?
- Acetylcholinesterase inhibitors and memantine for the treatment of psychotic symptoms in dementia.
- For people with [mild cognitive impairment] (MCI), acetylcholinesterase inhibitors should not be prescribed, except as part of properly constructed clinical studies.
- People with vascular dementia who develop non-cognitive symptoms or behaviour that challenges should not be prescribed acetylcholinesterase inhibitors, except as part of properly constructed clinical studies.
This page was last updated: 19 December 2013